CN1133461C - 虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用 - Google Patents
虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用 Download PDFInfo
- Publication number
- CN1133461C CN1133461C CNB001042548A CN00104254A CN1133461C CN 1133461 C CN1133461 C CN 1133461C CN B001042548 A CNB001042548 A CN B001042548A CN 00104254 A CN00104254 A CN 00104254A CN 1133461 C CN1133461 C CN 1133461C
- Authority
- CN
- China
- Prior art keywords
- huwen
- analgesic
- peptide
- analgesic peptide
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000239292 Theraphosidae Species 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000002708 spider venom Substances 0.000 title claims abstract description 5
- 230000000202 analgesic effect Effects 0.000 title abstract description 30
- 239000003814 drug Substances 0.000 title description 6
- 101500007657 Crotalus durissus terrificus Crotoxin chain gamma Proteins 0.000 claims abstract description 78
- 229940035676 analgesics Drugs 0.000 claims abstract description 25
- 239000000730 antalgic agent Substances 0.000 claims abstract description 25
- 239000000126 substance Substances 0.000 claims abstract description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- -1 valine Amino acid Chemical group 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 108090000312 Calcium Channels Proteins 0.000 abstract description 13
- 102000003922 Calcium Channels Human genes 0.000 abstract description 13
- 239000012528 membrane Substances 0.000 abstract description 7
- 230000003518 presynaptic effect Effects 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 4
- 230000005540 biological transmission Effects 0.000 abstract description 3
- 230000002980 postoperative effect Effects 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 3
- 208000030507 AIDS Diseases 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 208000004296 neuralgia Diseases 0.000 abstract description 2
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 19
- 230000000638 stimulation Effects 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 230000036407 pain Effects 0.000 description 14
- 230000008602 contraction Effects 0.000 description 13
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 12
- 229960004373 acetylcholine Drugs 0.000 description 12
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 239000002435 venom Substances 0.000 description 11
- 231100000611 venom Toxicity 0.000 description 11
- 210000001048 venom Anatomy 0.000 description 11
- 238000001467 acupuncture Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000000078 claw Anatomy 0.000 description 9
- 210000003405 ileum Anatomy 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- 230000037040 pain threshold Effects 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000003533 narcotic effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002837 heart atrium Anatomy 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000239290 Araneae Species 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 102000003691 T-Type Calcium Channels Human genes 0.000 description 3
- 108090000030 T-Type Calcium Channels Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 230000001550 time effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 150000001669 calcium Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241001157778 Haplopelma schmidti Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000008846 Neurocytoma Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- BPHHNXJPFPEJOF-UHFFFAOYSA-J chembl296966 Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C(N)C2=C(O)C(N=NC3=CC=C(C=C3OC)C=3C=C(C(=CC=3)N=NC=3C(=C4C(N)=C(C=C(C4=CC=3)S([O-])(=O)=O)S([O-])(=O)=O)O)OC)=CC=C21 BPHHNXJPFPEJOF-UHFFFAOYSA-J 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012581 double quantum filtered COSY Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229940083465 painzone Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001042548A CN1133461C (zh) | 2000-04-11 | 2000-04-11 | 虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用 |
US09/782,704 US6670329B2 (en) | 2000-04-11 | 2001-02-13 | Selenocosmia huwena toxin and analgesic uses thereof |
EP01107869A EP1161951B1 (en) | 2000-04-11 | 2001-04-10 | Selenocosmia huwena toxin and analgesic uses thereof |
DE60101977T DE60101977T2 (de) | 2000-04-11 | 2001-04-10 | Selenocosmia huwena Toxin und Verwendung als Analgetikum |
ES01107869T ES2215100T3 (es) | 2000-04-11 | 2001-04-10 | Toxina selenocosmia huwena y utilizaciones terapeuticas de la misma. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001042548A CN1133461C (zh) | 2000-04-11 | 2000-04-11 | 虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1307900A CN1307900A (zh) | 2001-08-15 |
CN1133461C true CN1133461C (zh) | 2004-01-07 |
Family
ID=4577244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB001042548A Expired - Fee Related CN1133461C (zh) | 2000-04-11 | 2000-04-11 | 虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US6670329B2 (zh) |
EP (1) | EP1161951B1 (zh) |
CN (1) | CN1133461C (zh) |
DE (1) | DE60101977T2 (zh) |
ES (1) | ES2215100T3 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008077276A1 (fr) * | 2006-12-25 | 2008-07-03 | Graduate School At Shenzhen, Tsinghua University | Solution injectable de venin d'araignée et mode d'élaboration correspondant |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2504023B1 (en) * | 2009-09-15 | 2015-07-15 | Alomone Preclinical Ltd. | Novel peptides isolated from spider venom, and uses thereof |
CN101845099A (zh) * | 2010-04-23 | 2010-09-29 | 中国药科大学 | 一种长效镇痛肽及其应用 |
EP2686340A2 (en) | 2011-03-16 | 2014-01-22 | Amgen Inc. | Potent and selective inhibitors of nav1.3 and nav1.7 |
CN103014048A (zh) * | 2012-11-19 | 2013-04-03 | 厦门北大之路生物工程有限公司 | 一种目的蛋白制备方法及其用途 |
CN102978211B (zh) * | 2012-11-19 | 2015-04-08 | 未名生物医药有限公司 | 一种目的蛋白制备方法及其用途 |
UY35397A (es) | 2013-03-12 | 2014-10-31 | Amgen Inc | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 |
AR096927A1 (es) | 2013-03-12 | 2016-02-10 | Amgen Inc | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 |
CN105732789A (zh) * | 2016-03-03 | 2016-07-06 | 中国科学院昆明动物研究所 | 森林山蛭镇痛肽mh2620及其基因和应用 |
CL2016002890A1 (es) * | 2016-11-14 | 2017-06-30 | Univ Antofagasta | Peptidos con actividad antimicrobiana |
CN110386970B (zh) * | 2019-07-29 | 2022-01-18 | 深圳佳肽生物科技有限公司 | 虎纹镇痛肽的合成方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE312913T1 (de) | 1996-08-02 | 2005-12-15 | Elan Pharm Inc | Klasse e-spannungsabh ngiger calciumkanale- antagonist und verfahren |
-
2000
- 2000-04-11 CN CNB001042548A patent/CN1133461C/zh not_active Expired - Fee Related
-
2001
- 2001-02-13 US US09/782,704 patent/US6670329B2/en not_active Expired - Lifetime
- 2001-04-10 DE DE60101977T patent/DE60101977T2/de not_active Expired - Lifetime
- 2001-04-10 ES ES01107869T patent/ES2215100T3/es not_active Expired - Lifetime
- 2001-04-10 EP EP01107869A patent/EP1161951B1/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008077276A1 (fr) * | 2006-12-25 | 2008-07-03 | Graduate School At Shenzhen, Tsinghua University | Solution injectable de venin d'araignée et mode d'élaboration correspondant |
Also Published As
Publication number | Publication date |
---|---|
EP1161951A1 (en) | 2001-12-12 |
DE60101977D1 (de) | 2004-03-18 |
CN1307900A (zh) | 2001-08-15 |
DE60101977T2 (de) | 2004-12-23 |
US6670329B2 (en) | 2003-12-30 |
ES2215100T3 (es) | 2004-10-01 |
EP1161951B1 (en) | 2004-02-11 |
US20030013647A1 (en) | 2003-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100610389B1 (ko) | 조눌린의 펩타이드 길항제와 그 사용 방법 | |
CN1133461C (zh) | 虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用 | |
EA200501007A1 (ru) | Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y2-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения | |
CN113880915B (zh) | 用于修复黏膜损伤或皮肤创伤的多肽及其应用 | |
CN108530527A (zh) | 一种多肽oa-gl21及其提纯方法与应用 | |
CN109265557B (zh) | 一种齐考诺肽和tat肽的融合多肽在制备药物中的应用 | |
CN101041692A (zh) | 蝎镇痛抗菌活性肽及其制备方法 | |
JP5802553B2 (ja) | ペプチジルジアシルグリセリド | |
CN109232744B (zh) | 改进型齐考诺肽 | |
EP1597271A2 (de) | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung | |
CN110772631A (zh) | 一组与烟碱乙酰胆碱受体具有高度亲和力能快速起效的眼镜蛇神经毒素分子在镇痛上的应用 | |
WO2004051280A2 (de) | Bestimmung agonistischer autoantikörper | |
CN112043821B (zh) | Sjmhe1多肽在治疗周围神经损伤药物中的用途 | |
WO2012037771A1 (zh) | 蝎毒肽及其制备方法与用途 | |
CN107987144B (zh) | 一种蜈蚣多肽SLP_SsTx及其编码基因和应用 | |
CN109232746B (zh) | 一种齐考诺肽和tat肽的融合多肽 | |
JP6991615B2 (ja) | アラリンを主成分とする尿毒症治療剤 | |
CN111892660B (zh) | 一种构建长qt综合征动物模型的多肽 | |
CN112076193B (zh) | 甲氧喹酸在制备用于治疗和/或预防以t-型钙通道为治疗靶点的疾病的药物中的应用 | |
DE102016125645A1 (de) | D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz | |
CN105440120A (zh) | 一种重组肿瘤坏死因子相关凋亡诱导配体蛋白及其应用 | |
US20240239841A1 (en) | Peptide and method for treating pain using the same | |
CN1128810C (zh) | 防治肝病的鲨鱼肝多肽结构及纯化 | |
RU99124561A (ru) | Способ профилактики и лечения остеоартроза, средство для его осуществления и способ получения средства для лечения остеоартроза | |
CN112972658B (zh) | 一种生长激素或其类似物的口服药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: WEIMING BIOMEDICINE CO., LTD. Free format text: FORMER NAME: BEIDAZHILU BIOLOGICAL ENGINEERING CO., LTD., XIAMEN |
|
CP01 | Change in the name or title of a patent holder |
Address after: 361004, International Trade Building or Cetra Building, Hubin South Road, Xiamen, Fujian Province, China. 9 Patentee after: SINOBIOWAY BIOMEDICINE CO., LTD. Patentee after: Hunan Normal University Address before: 361004, International Trade Building or Cetra Building, Hubin South Road, Xiamen, Fujian Province, China. 9 Patentee before: Xiamen Bioway Biotech Co., Ltd. Patentee before: Hunan Normal University |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040107 Termination date: 20190411 |